Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation
Andrew St. Martin(Johns Hopkins Hospital), Mary Eapen(Medical College of Wisconsin), Thomas DeSain(Harvard University), Paul Avillach(Harvard University), Vianney Jouhet(Harvard University), Emily Hughes(Harvard University), Arnaud Serret-Larmande(Harvard University), Danielle Pillon(Harvard University), Kyle Hebert(Harvard University), Jessica L. Carpenter(Harvard University), Patricia Steinert(Medical College of Wisconsin), Jason Stedman(Harvard University)
Cited by 0
Related Papers
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
|Journal of Clinical Oncology|2017|325
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
|Journal of Clinical Oncology|2021|247
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
|Blood|2021|163
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita
|Biology of Blood and Marrow Transplantation|2013|130